Wells Fargo & Company initiated coverage on shares of ORIC Pharmaceuticals (NASDAQ:ORIC - Free Report) in a report released on Thursday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $20.00 price objective on the stock.
Several other analysts have also recently issued reports on the company. Oppenheimer decreased their price objective on ORIC Pharmaceuticals from $17.00 to $15.00 and set an "outperform" rating on the stock in a report on Tuesday, August 13th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of ORIC Pharmaceuticals in a report on Monday, September 23rd. HC Wainwright reaffirmed a "buy" rating and set a $21.00 price objective on shares of ORIC Pharmaceuticals in a report on Wednesday, September 18th. Stifel Nicolaus initiated coverage on ORIC Pharmaceuticals in a report on Friday, September 6th. They set a "buy" rating and a $20.00 price objective on the stock. Finally, Wedbush reissued an "outperform" rating and set a $20.00 target price on shares of ORIC Pharmaceuticals in a research report on Tuesday, September 10th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $18.29.
Check Out Our Latest Analysis on ORIC
ORIC Pharmaceuticals Trading Down 0.4 %
Shares of NASDAQ:ORIC traded down $0.04 during mid-day trading on Thursday, reaching $9.38. The stock had a trading volume of 584,659 shares, compared to its average volume of 520,173. The business's 50 day moving average price is $9.73 and its 200 day moving average price is $9.26. ORIC Pharmaceuticals has a 1 year low of $5.85 and a 1 year high of $16.65. The company has a market cap of $661.68 million, a P/E ratio of -5.38 and a beta of 1.12.
ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Analysts predict that ORIC Pharmaceuticals will post -1.8 earnings per share for the current fiscal year.
Hedge Funds Weigh In On ORIC Pharmaceuticals
Hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD grew its position in ORIC Pharmaceuticals by 140.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,566,736 shares of the company's stock valued at $21,543,000 after acquiring an additional 915,175 shares during the last quarter. Bank of New York Mellon Corp grew its position in ORIC Pharmaceuticals by 62.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 186,484 shares of the company's stock valued at $1,318,000 after acquiring an additional 71,394 shares during the last quarter. Hennion & Walsh Asset Management Inc. bought a new position in ORIC Pharmaceuticals in the 2nd quarter valued at $724,000. Monaco Asset Management SAM grew its position in ORIC Pharmaceuticals by 132.0% in the 2nd quarter. Monaco Asset Management SAM now owns 301,650 shares of the company's stock valued at $2,133,000 after acquiring an additional 171,650 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in ORIC Pharmaceuticals in the 3rd quarter valued at $714,000. Institutional investors own 95.05% of the company's stock.
About ORIC Pharmaceuticals
(
Get Free Report)
ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
Read More
Before you consider ORIC Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ORIC Pharmaceuticals wasn't on the list.
While ORIC Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
